Tuesday, June 9, 2020, 5:00 PM – 6:30 PM

Oncology Grand Rounds: Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from PracticeA Complimentary CNE (NCPD) Live Webinar Series

Gynecologic Cancers

 
 
Faculty

Paula J Anastasia, RN, MN, AOCN
Gyn-Oncology Clinical Nurse Specialist
UCLA Medical Center
David Geffen School of Medicine
Los Angeles, California

Jennifer Filipi, MSN, NP
Massachusetts General Hospital
Center for Gynecologic Oncology
Boston, Massachusetts

David M O’Malley, MD
Professor
Division Director, Gynecologic Oncology
Co-Director
Gynecologic Oncology Phase I Program
The Ohio State University and
The James Cancer Center
Columbus, Ohio



Shannon N Westin, MD, MPH
Associate Professor
Director, Early Drug Development
Department of Gynecologic Oncology
and Reproductive Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Moderator

Neil Love, MD
Research To Practice
Miami, Florida


Topics for Discussion

  • Recommended genetic testing algorithms for patients with newly diagnosed ovarian cancer (OC); significance of BRCA1/2 mutations and other genomic abnormalities (eg, homologous recombination deficiency) that may predict sensitivity to a PARP inhibitor
  • Key clinical and biologic factors affecting the selection of first-line and maintenance therapy for patients with newly diagnosed OC
  • Similarities and differences among the 3 PARP inhibitors FDA approved for patients with OC; selecting from these agents in clinical practice
  • Practical administration of PARP inhibitors as maintenance therapy for patients responding to first-line chemotherapy
  • Available data with other promising strategies incorporating PARP inhibitors alone or in combination with anti-angiogenic agents or immune checkpoint inhibitors as maintenance therapy for newly diagnosed OC (eg, from the PAOLA-1, VELIA, ATHENA, FIRST and DUO-O trials)
  • Spectrum of toxicities associated with various PARP inhibitors: gastrointestinal toxicities, anemia, thrombocytopenia, et cetera; indications for dose modification, delay or interruption
  • Incidence of microsatellite instability (MSI)-high advanced endometrial cancer and PD-L1-positive advanced cervical cancer; current indications for MSI and PD-L1 testing
  • Unique supportive care considerations for patients with endometrial or cervical cancer who are receiving therapy with an anti-PD-1 antibody
  • Patient and clinical factors affecting the selection of first-line therapy for newly diagnosed endometrial or cervical cancer
  • Published research database with pembrolizumab for recurrent or metastatic cervical cancer (KEYNOTE-158 trial); definition of PD-L1 positivity and its impact on the activity of pembrolizumab
  • FDA approval of pembrolizumab for patients with PD-L1-positive recurrent or metastatic cervical cancer who experience disease progression on or after chemotherapy; patient selection for its use in routine clinical practice; current role and optimal integration
  • Biologic rationale for combining lenvatinib with pembrolizumab for patients with metastatic endometrial cancer who experience disease progression after systemic therapy
  • Data from the KEYNOTE-146 trial leading to the recent FDA approval of pembrolizumab/lenvatinib for patients with previously treated, advanced microsatellite-stable endometrial cancer who are ineligible for curative surgery or radiation therapy; optimal integration into current practice
  • Other promising agents and strategies under investigation for advanced gynecologic cancers

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of gynecologic cancers.

Learning Objectives and Goals
Upon completion of this activity, participants should be able to:

  • Consider the FDA approvals of olaparib and niraparib as maintenance therapy after first-line platinum-based chemotherapy for advanced ovarian cancer (OC), and counsel patients with and without BRCA mutations regarding appropriate treatment recommendations.
  • Evaluate available clinical trial data with olaparib/bevacizumab as maintenance therapy for patients with newly diagnosed advanced OC responding after first-line platinum-taxane chemotherapy with bevacizumab to determine the role of this novel strategy in clinical practice.
  • Appreciate the biologic rationale for and available data with the use of PARP inhibitors in combination with chemotherapy, and consider the clinical and research implications for the management of OC.
  • Understand the importance of microsatellite instability (MSI) testing for patients with OC, endometrial cancer (EC) and cervical cancer (CC), and identify the benefits observed with anti-PD-1/PD-L1 antibodies for high MSI (MSI-H) or mismatch repair deficient (dMMR) disease.
  • Recognize the FDA approval of pembrolizumab in combination with lenvatinib for advanced, recurrent EC that is not MSI-H or dMMR in order to identify patients appropriate for this novel approach.
  • Review published research data documenting the efficacy and safety of anti-PD-1 monotherapy for PD-L1-positive recurrent or metastatic CC that progresses on or after chemotherapy, and use this information to educate patients about the benefits and risks associated with this therapy.
  • Describe the biologic rationale for, published research data with and ongoing evaluation of immune checkpoint inhibitors alone or in combination with chemotherapy, other immunotherapies and targeted treatments in the management of OC, EC and CC, and effectively prioritize clinical trial opportunities for eligible patients.
  • Assess the toxicities associated with PARP inhibitors, immune checkpoint inhibitors and other therapies commonly used for gynecologic cancers, and offer patients supportive management strategies to minimize and ameliorate these side effects.
  • Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with OC, CC and EC to optimize clinical and quality-of-life outcomes.
Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by RTP.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form, which will be emailed to attendees after the event.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for CNE (NCPD) credit to utilize this program for ONCC certification or renewal. http://www.ResearchToPractice.com/Meetings/ONS2020/GynOnc/ILNA

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE (NCPD) activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYMs Anastasia and Ms Filipi have no relevant conflicts of interest to disclose. The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr O’MalleyAdvisory Committee: AbbVie Inc, Agenus Inc, Ambry Genetics, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genelux, Genentech, a member of the Roche Group, GOG Foundation Inc, ImmunoGen Inc, Janssen Biotech Inc, Leap Therapeutics Inc, Merck, Myriad Genetic Laboratories Inc, Novocure, Regeneron Pharmaceuticals Inc, Tarveda Therapeutics, Tesaro, A GSK Company; Consulting Agreements: AbbVie Inc, Agenus Inc, Ambry Genetics, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Genmab, GOG Foundation Inc, ImmunoGen Inc, Novocure, Regeneron Pharmaceuticals Inc, Seattle Genetics, Tesaro, A GSK Company; Contracted Research: AbbVie Inc, Agenus Inc, Ajinomoto Co Inc, Amgen Inc, Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Clovis Oncology, Daré Bioscience, Eisai Inc, EMD Serono Inc, Ergomed Plc, Genentech, a member of the Roche Group, Genmab, GlaxoSmithKline, GOG Foundation Inc, ImmunoGen Inc, Iovance Biotherapeutics Inc, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Ludwig Institute for Cancer Research Ltd, Merck, New Mexico Cancer Care Alliance, Novocure, PRA Health Sciences, Regeneron Pharmaceuticals Inc, Seattle Genetics, Stemcentrx, Syneos Health, Tesaro, A GSK Company, TRACON Pharmaceuticals Inc, VentiRx Pharmaceuticals Inc. Data and Safety Monitoring Board/Committee: Marker Therapeutics Inc. Dr WestinConsulting Agreements: AstraZeneca Pharmaceuticals LP, Circulogene, Clovis Oncology, Genentech, a member of the Roche Group, Merck, Novartis, Pfizer Inc, Tesaro, A GSK Company; Contracted Research: ArQule Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Cotinga Pharmaceuticals, Genentech, a member of the Roche Group, Novartis, Tesaro, A GSK Company; Data and Safety Monitoring Board/Committee: Xenetic Biosciences.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

RTP CNE (NCPD) planning committee members, staff and reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc and Merck.